Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

2.810 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.810
Bid (Size) 2.750 (600)
Ask (Size) 2.900 (500)
Prev. Close 2.810
Today's Range 2.810 - 2.810
52wk Range 0.6400 - 6.260
Shares Outstanding 5,704,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care
Via Investor Brand Network

Performance

YTD
-26.8%
-26.8%
1 Month
-21.1%
-21.1%
3 Month
-33.1%
-33.1%
6 Month
-39.2%
-39.2%
1 Year
+132.2%
+132.2%

More News

Read More
BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
Via Investor Brand Network
Topics Intellectual Property
When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
Via Investor Brand Network
InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks –  LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
Via Investor Brand Network
Topics Intellectual Property
Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit at Morehouse College
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market
Via Investor Brand Network
Topics Intellectual Property
News headline image
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
Via ACCESS Newswire
News headline image
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
Via ACCESS Newswire
News headline image
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
Via ACCESS Newswire
News headline image
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
Via ACCESS Newswire
News headline image
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Via Newsfile

Frequently Asked Questions

Is Lixte Biotechnology Holdings, Inc. - Common Stock publicly traded?
Yes, Lixte Biotechnology Holdings, Inc. - Common Stock is publicly traded.
What exchange does Lixte Biotechnology Holdings, Inc. - Common Stock trade on?
Lixte Biotechnology Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock?
The ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock is LIXT on the Nasdaq Stock Market
What is the current price of Lixte Biotechnology Holdings, Inc. - Common Stock?
The current price of Lixte Biotechnology Holdings, Inc. - Common Stock is 2.810
When was Lixte Biotechnology Holdings, Inc. - Common Stock last traded?
The last trade of Lixte Biotechnology Holdings, Inc. - Common Stock was at 03/04/26 04:00 PM ET
What is the market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock?
The market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock is 16.03M
How many shares of Lixte Biotechnology Holdings, Inc. - Common Stock are outstanding?
Lixte Biotechnology Holdings, Inc. - Common Stock has 16M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.